GlassScriptPhysician profile
Obai Abdullah
NPI 1417263450
$4,168.60
in general payments reported to CMS, 2019-2025
13 companies · $63.32 in 2025
The $63.32 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $3,038 · 2021: $75.71 · 2022: $269 · 2023: $179 · 2024: $134 · 2025: $63.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $376.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,515.55 | 2019-2020 | |
| Edwards Lifesciences Corporation | $1,420.15 | 2020 | |
| Abiomed | $235.16 | 2021-2024 | Impella |
| Chiesi USA, INC. | $209.23 | 2020-2022 | |
| Medtronic, INC. | $135.35 | 2022-2023 | Telescope, Onyx Frontier |
| Shockwave Medical, INC | $133.21 | 2022-2025 | |
| Boston Scientific Corporation | $114.55 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $101.93 | 2024 | Verquvo |
| Cardiovascular Systems INC. | $101.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $100.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $62.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.60 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.43 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obai Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.